Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop an alternative delivery mechanism for patients who can benefit from ACA-11 (pritumumab), Nascent's lead monoclonal antibody cancer treatment asset, for the treatment of Brain Cancer.
Lead Product(s): Pritumumab
Therapeutic Area: Oncology Product Name: ACA-11
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nascent Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 19, 2024